Kapitalbedarf (in Euro): 2.500.000
Datum des Förderbescheids: 30.04.2020
Geschäftskonzept: Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Thanks to a unique screening approach, Eisbach will establish cures for tumors that currently have no viable therapeutic option. In combination with existing drugs, our molecules will also make current therapies much more effective and greatly reduce their negative side-effects. By inhibiting genome evolution, we will furthermore increase the number of patients that can benefit from cancer immunotherapy. Eisbach will beat cancer at its own game.